BR0015607A - Genoma do inter-subtipo do hiv-1 ( c/b') e seu uso - Google Patents

Genoma do inter-subtipo do hiv-1 ( c/b') e seu uso

Info

Publication number
BR0015607A
BR0015607A BR0015607-8A BR0015607A BR0015607A BR 0015607 A BR0015607 A BR 0015607A BR 0015607 A BR0015607 A BR 0015607A BR 0015607 A BR0015607 A BR 0015607A
Authority
BR
Brazil
Prior art keywords
hiv
subtype
genome
inter
seq
Prior art date
Application number
BR0015607-8A
Other languages
English (en)
Inventor
Ralf Wagner
Hans Wolf
Marcus Graf
Original Assignee
Geneart Gmbh Gessellschaft F R
Yiming Shao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneart Gmbh Gessellschaft F R, Yiming Shao filed Critical Geneart Gmbh Gessellschaft F R
Priority to BR0015607-8A priority Critical patent/BR0015607A/pt
Publication of BR0015607A publication Critical patent/BR0015607A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"GENOMA DO INTER-SUBTIPO DO HIV-1(C/B') E SEU USO". A invenção refere-se a um polinucleotídeo, compreendendo uma seq³ência de ácido nucléico de acordo com SEQ ID NO: 1, 2 ou 3, seus fragmentos ou derivados, ou um polinucleotídeo hibridizado com a seq³ência de ácido nucléico de acordo com SEQ ID NO: 1, 2 ou 3. A invenção diz respeito ainda a polipeptídeos codificados a partir da dita sequência de nucleotídeo, ou fragmento, ou derivado da seq³ência de ácido nucléico de acordo com SEQ ID NO: 1, 2 ou 3. Os polinucleotídeos e polipeptídeos podem ser usados como medicamentos, vacinas ou diagnósticos, em particular, para o tratamento, profilaxia e diagnose de infecções por HIV.
BR0015607-8A 1999-11-16 2000-11-16 Genoma do inter-subtipo do hiv-1 ( c/b') e seu uso BR0015607A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR0015607-8A BR0015607A (pt) 1999-11-16 2000-11-16 Genoma do inter-subtipo do hiv-1 ( c/b') e seu uso

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19955089 1999-11-16
PCT/DE2000/004073 WO2001036614A2 (de) 1999-11-16 2000-11-16 Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
BR0015607-8A BR0015607A (pt) 1999-11-16 2000-11-16 Genoma do inter-subtipo do hiv-1 ( c/b') e seu uso

Publications (1)

Publication Number Publication Date
BR0015607A true BR0015607A (pt) 2002-07-30

Family

ID=7929215

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015607-8A BR0015607A (pt) 1999-11-16 2000-11-16 Genoma do inter-subtipo do hiv-1 ( c/b') e seu uso

Country Status (14)

Country Link
US (2) US7332588B1 (pt)
EP (1) EP1240333B1 (pt)
CN (2) CN101586106B (pt)
AP (1) AP1674A (pt)
AT (1) ATE391785T1 (pt)
AU (1) AU784635B2 (pt)
BR (1) BR0015607A (pt)
CA (1) CA2391560A1 (pt)
DE (2) DE10056747A1 (pt)
ES (1) ES2303513T3 (pt)
HK (1) HK1046428A1 (pt)
OA (1) OA12156A (pt)
WO (1) WO2001036614A2 (pt)
ZA (1) ZA200204047B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
AU2002362368B2 (en) * 2001-09-20 2006-09-21 Glaxo Group Limited HIV-gag codon-optimised DNA vaccines
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
US20090060947A1 (en) * 2006-05-19 2009-03-05 Sanofi Pasteur, Inc. Immunological compositions
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
CA2789483A1 (en) * 2010-03-02 2011-09-09 International Aids Vaccine Initiative Novel hiv-1 envelope glycoprotein
AU2012308149A1 (en) 2011-09-12 2014-03-27 Sheena Mary Geraldine MCCORMACK Methods and compositions for raising an immune response to HIV
CA2930695C (en) * 2013-11-14 2024-05-14 Inovio Pharmaceuticals, Inc. Hiv-1 env dna vaccine plus protein boost
CN105586319B (zh) * 2014-10-20 2021-01-08 中国疾病预防控制中心性病艾滋病预防控制中心 复制型痘苗病毒载体艾滋病疫苗
CN107090019B (zh) * 2017-01-23 2018-11-23 张帅 人类免疫缺陷病毒重组蛋白
CN110627911B (zh) * 2019-10-14 2022-11-22 吉林大学 一种可诱导hiv-1广谱中和抗体的包膜蛋白三聚体免疫原及用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
ATE208813T1 (de) 1988-02-16 2001-11-15 Greatbatch Gen Aid Ltd Modifizierte zellen mit resistenz gegen retroviralinfektionen
US5580761A (en) 1988-02-16 1996-12-03 Greatbatch Gen-Aid Ltd. Method of conferring resistance to immunodeficiency viral infection
EP1369427A3 (en) 1988-06-09 2004-05-12 Innogenetics N.V. HIV-3 retrovirus strains and their use
EP0440749B1 (en) * 1988-08-31 1997-05-28 Aprogenex, Inc. Manual in situ hybridization assay
EP0434713B1 (en) 1988-09-13 1994-10-12 Chiron Corporation Hiv-1 envelope muteins lacking hypervariable domains
ATE125157T1 (de) 1990-04-03 1995-08-15 Genentech Inc Methoden und zusammensetzungen zur impfung gegen hiv.
DK0550691T3 (da) 1990-09-27 1996-07-29 Pasteur Institut Antistofinducerende peptider, som inhiberer retrovira af HIV-typen, og antistoffer, som er specifikke for disse peptider
US5847096A (en) 1991-08-30 1998-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA constructs encoding CD4 fusion proteins
EP0725838A4 (en) 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
WO1995016710A1 (en) 1993-12-13 1995-06-22 United Biomedical, Inc. Specific hyperimmune anti-hiv globulin for passive immunization
US5599662A (en) * 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
DE19513152A1 (de) * 1995-04-07 1996-10-10 Bundesrep Deutschland Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
GB9621679D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Improved retroviral vectors
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6958226B1 (en) * 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1141313A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000029561A2 (en) * 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope

Also Published As

Publication number Publication date
ATE391785T1 (de) 2008-04-15
ES2303513T3 (es) 2008-08-16
OA12156A (en) 2006-05-08
AP2002002508A0 (en) 2002-06-30
AU2350401A (en) 2001-05-30
US7323557B2 (en) 2008-01-29
ZA200204047B (en) 2002-12-20
EP1240333A2 (de) 2002-09-18
EP1240333B1 (de) 2008-04-09
WO2001036614A2 (de) 2001-05-25
HK1046428A1 (en) 2003-01-10
WO2001036614A3 (de) 2002-02-28
CN101586106A (zh) 2009-11-25
US7332588B1 (en) 2008-02-19
AU784635B2 (en) 2006-05-18
US20070003572A1 (en) 2007-01-04
CN101586106B (zh) 2015-04-01
DE50015096D1 (de) 2008-05-21
CA2391560A1 (en) 2001-05-25
AP1674A (en) 2006-10-30
CN1423698A (zh) 2003-06-11
DE10056747A1 (de) 2001-05-31

Similar Documents

Publication Publication Date Title
BR0015607A (pt) Genoma do inter-subtipo do hiv-1 ( c/b') e seu uso
JP2004511201A5 (pt)
US5688637A (en) Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the disease due to these viruses
DK168061B1 (da) Med mrna hybridiserbart anti-viralt middel
JP2003527079A5 (pt)
BR9814912A (pt) Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
JP2018110582A5 (pt)
EP2195433B1 (en) Detection of toxigenic strains of clostridium difficile
RU2012102339A (ru) Полипептиды из neisseria meningitidis
PT1037909E (pt) Síndrome multi-sistémica do definhamento pós-desmame de porcos
EP0727497A1 (en) Primers and probes for the detection of HIV
WO2021000968A3 (zh) 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
WO2001066597A3 (en) Inflammation-related gene
BR0005804A (pt) Sequências de nucleotìdeos que codificam o genezwa1
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
JP2020509770A5 (pt)
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
WO1998006841A3 (en) Two human nsp-like proteins
CA2342770A1 (en) Ly6h gene
Kim et al. Characterization of the complete mitochondrial genome of Diphyllobothrium nihonkaiense (Diphyllobothriidae: Cestoda), and development of molecular markers for differentiating fish tapeworms
Zhang et al. Genotypic analysis on the ORF-K1 gene of human herpesvirus 8 from patients with Kaposi's sarcoma in Xinjiang, China
IL159047A0 (en) Pharmacological applications of mitochondrial dna assay
NO20023248D0 (no) Nukleinsyrer som koder for (poly)peptider med CHIPS-aktivitet
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
Vogeli et al. Proposed alignment of helical interruptions in the two subunits of the basement membrane (type IV) collagen

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: YIMING SHAO (CN) , GENEART GMBH (DE)

B25G Requested change of headquarter approved

Owner name: YIMING SHAO (CN) , GENEART GMBH (DE)

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: YIMING SHAO (CN) , GENEART GMBH (DE)

Free format text: AFIM DE ATENDER AS SEGUNDAS ALTERACOES DE NOME E SEDE REQUERIDAS ATRAVES DA PETICAO NO 020070167351/RJ DE 27/11/2007, RECOLHA OS VALORES REFERENTES AOS ATOS REQUERIDOS.

B25D Requested change of name of applicant approved

Owner name: YIMING SHAO (CN) , GENEART AG (DE)

Free format text: ALTERADO DE: GENEART GMBH

B25G Requested change of headquarter approved

Owner name: YIMING SHAO (CN) , GENEART AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070167351/RJ DE 27/11/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: O DEPOSITANTE DEVERA ULTILIZAR A PETICAO CONTIDA NO ANEXO II DA RESOLUCAO INPI NO 207/09 ( DECLARACAO NEGATIVA DE ACESSO ) FACE AO ACIMA EXPOSTO, O DEPOSITANTE DEVERA APRESENTAR A PETICAO DEVIDA PARA O CUMPRIMENTO DESTA EXIGENCIA EM ATE 60 ( SESSENTA ) DIAS, CONTADOS A PARTIR DA DATA DE PUBLICACAO NA RPI DE ACORDO COM O ART. 34 ( II ) DA LPI PARA QUE SE DE INICIO AO EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]